Literature DB >> 27302309

Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma.

Nozomi Matsumura1, Nozomi Nakajima1, Tatsuya Yamazaki1, Takuro Nagano2, Kaie Kagoshima2, Sumihito Nobusawa1, Hayato Ikota1, Hideaki Yokoo1.   

Abstract

Epithelioid glioblastoma (E-GBM) is a rare variant of glioblastoma (GBM), characterized by epithelioid cells with eosinophilic round cytoplasm devoid of stellate cytoplasmic processes. A number of studies have demonstrated that more than half of E-GBMs harbor a valine to glutamic acid substitution at position 600 of the serine/threonine-protein kinase BRAF (BRAF V600E). However, there are no previous reports on E-GBM with telomerase reverse transcriptase (TERT) promoter mutation in addition to BRAF V600E mutation. Here, we report an E-GBM case in an 18-year-old man with BRAF V600E and TERT promoter mutations. The tumor composed of 80% E-GBM and 20% diffuse astrocytoma-like components, and BRAF V600E and TERT promoter mutations were detected in both. E-GBM generally arises as a primary lesion; however, a few previous cases have been demonstrated to accompany low-grade areas. Demonstration of concurrent BRAF V600E and TERT promoter mutations in low- and high-grade lesions strongly suggested their identical origin, and acquisition of each mutation may be an early event, possibly playing a pivotal role in the genesis and subsequent progression to E-GBM.
© 2016 Japanese Society of Neuropathology.

Entities:  

Keywords:  BRAF; TERT promoter; epithelioid glioblastoma; low-grade astrocytoma; tumorigenesis

Mesh:

Substances:

Year:  2016        PMID: 27302309     DOI: 10.1111/neup.12318

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  9 in total

Review 1.  When the Ends Are Really the Beginnings: Targeting Telomerase for Treatment of GBM.

Authors:  Saumya R Bollam; Michael E Berens; Harshil D Dhruv
Journal:  Curr Neurol Neurosci Rep       Date:  2018-03-10       Impact factor: 5.081

2.  The genetic landscape of anaplastic pleomorphic xanthoastrocytoma.

Authors:  Joanna J Phillips; Henry Gong; Katharine Chen; Nancy M Joseph; Jessica van Ziffle; Boris C Bastian; James P Grenert; Cassie N Kline; Sabine Mueller; Anuradha Banerjee; Theodore Nicolaides; Nalin Gupta; Mitchel S Berger; Han S Lee; Melike Pekmezci; Tarik Tihan; Andrew W Bollen; Arie Perry; Joseph T C Shieh; David A Solomon
Journal:  Brain Pathol       Date:  2018-11-06       Impact factor: 6.508

3.  Clinicopathological characteristics and treatment outcomes of epithelioid glioblastoma.

Authors:  Kaijun Sun; Xingwang Zhou; Tengfei Li; Mingrong Zuo; Junhong Li; Yanhui Liu
Journal:  Neurosurg Rev       Date:  2021-02-17       Impact factor: 3.042

Review 4.  The evolution of pleomorphic xanthoastrocytoma: from genesis to molecular alterations and mimics.

Authors:  Swati Mahajan; Iman Dandapath; Ajay Garg; Mehar C Sharma; Vaishali Suri; Chitra Sarkar
Journal:  Lab Invest       Date:  2022-01-14       Impact factor: 5.662

Review 5.  Glioma Subclassifications and Their Clinical Significance.

Authors:  Ricky Chen; Matthew Smith-Cohn; Adam L Cohen; Howard Colman
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

6.  Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis.

Authors:  Andrey Korshunov; Lukas Chavez; Tanvi Sharma; Marina Ryzhova; Daniel Schrimpf; Damian Stichel; David Capper; Dominik Sturm; Marcel Kool; Antje Habel; Bette K Kleinschmidt-DeMasters; Marc Rosenblum; Oksana Absalyamova; Andrey Golanov; Peter Lichter; Stefan M Pfister; David T W Jones; Arie Perry; Andreas von Deimling
Journal:  Brain Pathol       Date:  2017-10-30       Impact factor: 6.508

7.  Clinicopathological, Immunohistochemical and Molecular Genetic Study on Epithelioid Glioblastoma: A Series of Fifteen Cases with Literature Review.

Authors:  Ying Zeng; Xiangfeng Zhu; Yali Wang; Bo Liu; Xin Yang; Qiushi Wang; Juan Du; Yu Ma; Li Lin; Ping Fu; Hualiang Xiao; Qiao-Nan Guo
Journal:  Onco Targets Ther       Date:  2020-05-08       Impact factor: 4.147

8.  Biology and grading of pleomorphic xanthoastrocytoma-what have we learned about it?

Authors:  Rachael Vaubel; Valentina Zschernack; Quynh T Tran; Sarah Jenkins; Alissa Caron; Dragana Milosevic; James Smadbeck; George Vasmatzis; Daniela Kandels; Astrid Gnekow; Christof Kramm; Robert Jenkins; Benjamin R Kipp; Fausto J Rodriguez; Brent A Orr; Torsten Pietsch; Caterina Giannini
Journal:  Brain Pathol       Date:  2020-08-04       Impact factor: 6.508

9.  KMT2A promotes melanoma cell growth by targeting hTERT signaling pathway.

Authors:  Changlin Zhang; Chen Song; Tianze Liu; Ranran Tang; Miao Chen; Fan Gao; Binyi Xiao; Ge Qin; Fen Shi; Wenbin Li; Yixin Li; Xiaoyan Fu; Dingbo Shi; Xiangsheng Xiao; Lan Kang; Wenlin Huang; Xiaojun Wu; Bing Tang; Wuguo Deng
Journal:  Cell Death Dis       Date:  2017-07-20       Impact factor: 8.469

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.